A Dose-block Randomized, Double-blind, Placebo-controlled, Single and Multiple Dosing, Dose-escalation, Phase 1 Clinical Trial to Evaluate the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics, Food Effect, Ethnic Difference of BnH-015B After Oral Administration in Healthy Adult Korean and Caucasian Male Volunteers and in Patients With Moderate Alzheimer's Disease
Latest Information Update: 09 Jan 2025
At a glance
- Drugs BnH 015B (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors BnH Research
Most Recent Events
- 07 Jan 2025 Status changed from not yet recruiting to recruiting.
- 08 Aug 2024 New trial record